Background: Measurement of C-peptide in serum is useful for presumption of pancreatic β-cell function, preventing influence of exogenous insulin or insulin autoantibody. It has been thought that it is difficult to measure without being influenced of proinsulin. Moreover, a C-peptide is small molecule it has been thought that it is difficult to measure using two monoclonal antibodies. Therefore we have developed the highly sensitive and specific assay for C-peptide in serum and plasma on the LUMIPULSE system. The system is a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, that uses AMPPD as a substrate for alkaline phosphatase and ferrite micro-particles as a solid phase. Methods: Utilizing a monoclonal antibody that recognizes N-terminal of the C-peptide molecule realized the specificity of the assay. It is measured correctly, without influencing C-peptide of the molecule used as proinsulin or the fragmentized C-peptide by the singularity of this antibody. The assay format for C-peptide was based on 2-step sandwich principle. The incubation times for first and second reactions were 10 minutes each. The amount of detecting antibodies bound on the particle were determined by measuring chemiluminescent light emission of the AMPPD substrate. Results: The evaluation was performed based on the NCCLS guideline. Representative data from some of the assay are summarized in the table below:
Detection interval
0.02 -30ng/mL Imprecision (CV) 2.64% (2.40ng/mL) 1.62% (8.45ng/mL) Limit of detection 0.004ng/mL Limit of quantitation 0.02ng/mL Cross-reactivity pro-insulin, 0.6%
Conclusions: The C-peptide assay on the system showed good sensitivity, specificity and precision. Accordingly it was concluded that the C-peptide assay was of use to diagnose glucose metabolic disorder and to monitor the disease status of diabetes.
